Plans announced by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) to develop and publish a guideline on bioequivalence for modified-release products have been commended by the International Generic and Biosimilar Medicines Association (IGBA).
Bioequivalence for modified-release products was one of three new areas for harmonization that the ICH assembly adopted
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?